| Bioactivity | Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research[1]. |
| Target | TRAIL-R2 |
| Invitro | Lexatumumab 与顺铂 Cisplatin (HY-17394) 联合可协同抑制细胞生长和增强凋亡死亡[1]。Lexatumumab (0-10 µg/ml, 72 h) 在不同的黑色素瘤细胞系中诱导不同程度的细胞死亡[2]。 Cell Viability Assay[2] Cell Line: |
| In Vivo | Lexatumumab (10mg/kg，静脉注射，每周两次)联合 Dacarbazine (HY-B0078) 可增加小鼠体内抗肿瘤效果[2]。 Animal Model: |
| Name | Lexatumumab |
| CAS | 845816-02-6 |
| Molar Mass | 143.6 (kDa) |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66. [2]. Engesæter B, et al. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492. |